Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2018 Oct 25;11:7493–7501. doi: 10.2147/OTT.S161852

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2018 Zhou et al. This work is published and licensed by Dove Medical Press Limited

The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.

PMC Copyright notice

FAM129B was associated with worse prognosis of NSCLC patients.

Notes: (A) Results of online software survival prediction (KM plotter). The survival time of patients with higher FAM129B mRNA expression was significantly shorter than that of patients with lower FAM129B mRNA expression. Representative figures of FAM129B expression in normal bronchial (B), alveolar epithelial (C), squamous cell lung carcinoma (D) and lung adenocarcinoma (E). Magnification, 400×, scale bar=50 µm. FAM129B presented higher expression levels in NSCLC tissue samples than in corresponding noncancerous tissues (F, 100×; G and H, inset, 400×, scale bar=50 µm). Kaplan–Meier survival analysis revealed that patients with positive FAM129B expression presented poorer overall survival than did those with negative FAM129B expression (I).

Abbreviation: NSCLC, non-small-cell lung cancer.